Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
Authors:
Open Access
- 9 January 2021
- journal article
- research article
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 22 (1) , 1-10
Abstract
Background: The CGRP antagonists offer a novel therapeutic approach in migraine. Their utility in patients with severe forms of chronic migraine is a subject of particular interest. We present outcomes of 9 months of erenumab treatment in a cohort of patients with difficult-to-control chronic migraine, all of whom had prior unsatisfactory response to onabotulinumtoxinA. Methods: We offered erenumab to 98 patients with a prior unsatisfactory response to onabotulinumtoxinA. Eighty of 98 had trialled greater occipital nerve injections (82%), 32/98 peripheral neurostimulation (33%) and 18/98 intravenous dihydroergotamine (18%). Thirty eight of 98 (39%) met the definition of triptan overuse and 43/98 (44%) analgesic overuse. All patients met the EHF criteria for ‘resistant migraine’. Outcome measures (recorded monthly) included days with headache limiting activities of daily living (“red”), not limiting (“amber”), headache free (“green”), and requiring triptans or other analgesics. Quality of life scores - headache impact test 6 (HIT-6), patient health questionnaire 9 (PHQ-9) and pain disability index (PDI) - were also measured. Results: Mean number of red days improved by − 6.4 days (SE 0.67, 95%CI − 7.7 to − 5.1, p=0.001) at 3 months; − 6.8 days (SE 0.96, 95%CI − 8.80 to − 4.9, p=0.001) at 6 months and − 6.5 days (SE 0.86, 95%CI − 8.3 to − 4.8, p=0.001) at 9 months. Repeated measures ANOVA confirmed improvements in the number of red (p=0.001), green (p=0.001), triptan (p=0.001) and painkiller days (p=0.001) as well as scores of the HIT-6 (p=0.001), PHQ-9 (p=0.001), and PDI (p=0.001) across the duration of study. Conclusion: We observed improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment.Keywords
This publication has 35 references indexed in Scilit:
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trialThe Lancet Neurology, 2017
- TEV-48125 for the preventive treatment of chronic migraineNeurology, 2016
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyThe Lancet Neurology, 2015
- What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patientsCephalalgia, 2013
- Responsiveness and Minimal Clinically Important Change of the Pain Disability Index in Patients With Chronic Back PainSpine, 2012
- Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysisCanadian Medical Association Journal, 2011
- Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraineCephalalgia, 2010
- Headache Impact Test-6 (HIT-6) Scores for Migraine Patients: Their Relation to Disability as Measured from a Headache DiaryJournal of Clinical Neurology, 2008
- Monitoring Depression Treatment Outcomes With the Patient Health Questionnaire-9Medical Care, 2004
- The Pain Disability Index: psychometric propertiesPain, 1990